Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (R43)

The summary for the Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (R43) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (R43): This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose preclinical studies to advance the development of biomarkers or treatments for rare musculoskeletal, rheumatic or skin diseases. Rare diseases have a prevalence of fewer than 200,000 affected individuals in the United States. Also eligible for potential funding through this initiative are studies of FDA-designated orphan products for musculoskeletal, rheumatic or skin diseases. See the NIAMS Long-Range Plan for more information about NIAMS research interests (http://www.niams.nih.gov/About_Us/Mission_and_Purpose/long_range.asp).